Recently added
This page was added on 27 June 2024.
Updates made
This page was updated on [date-counter-updated-date]. View history of updates
Monoclonal antibody for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract infection in:
- Neonates and infants born during or entering their first RSV season
- Children up to 24 months of age who remain vulnerable to severe RSV disease throughout their second RSV season
Siliconised Luer lock Type 1 glass prefilled syringe with a Fluro Tec-coated plunger stopper
Beyfortus 50mg solution for injection in prefilled syringe with a purple plunger rod: Each prefilled syringe contains 50mg of nirsevimab in 0.5mL (100mg/mL)
Beyfortus 100mg solution for injection in prefilled syringe with a light blue plunger rod: Each pre-filled syringe contains 100mg of nirsevimab in 1mL (100mg/mL)
Also contains:
- histidine
- histidine hydrochloride
- monohydrate
- arginine hydrochloride
- sucrose
- polysorbate 80
- water
For Product Information and Consumer Medicine Information about Beyfortus (Nirsevimab) visit the Therapeutic Goods Administration website.
Additional information
For detailed advice on dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.